193 related articles for article (PubMed ID: 33342816)
1. Yet another utility for isocitrate dehydrogenase.1: Can it serve as an immunomarker to assess tumor margins in gliomas?
Rao S; Rajkumar A; Sundaram S; Joyce ME; Duvuru P
J Cancer Res Ther; 2020; 16(6):1476-1481. PubMed ID: 33342816
[TBL] [Abstract][Full Text] [Related]
2. Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes.
Capper D; Sahm F; Hartmann C; Meyermann R; von Deimling A; Schittenhelm J
Am J Surg Pathol; 2010 Aug; 34(8):1199-204. PubMed ID: 20661018
[TBL] [Abstract][Full Text] [Related]
3. Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma.
Raghunathan A; Olar A; Vogel H; Parker JR; Coventry SC; Debski R; Albarracin CT; Aldape KD; Cahill DP; Powell SZ; Fuller GN
Ann Diagn Pathol; 2012 Aug; 16(4):255-9. PubMed ID: 22445362
[TBL] [Abstract][Full Text] [Related]
4. IDH1 status is significantly different between high-grade thalamic and superficial gliomas.
Zuo M; Li M; Chen N; Yu T; Kong B; Liang R; Wang X; Mao Q; Liu Y
Cancer Biomark; 2017 Aug; 20(2):183-189. PubMed ID: 28869450
[TBL] [Abstract][Full Text] [Related]
5. [Expression of isocitrate dehydrogenase 1 gene R132H and its diagnostic application in glioma].
PIAO YS; LU DH; ZHANG XJ; TANG GC; YANG H
Zhonghua Bing Li Xue Za Zhi; 2011 Mar; 40(3):156-60. PubMed ID: 21575384
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemistry on IDH 1/2, ATRX, p53 and Ki-67 substitute molecular genetic testing and predict patient prognosis in grade III adult diffuse gliomas.
Takano S; Ishikawa E; Sakamoto N; Matsuda M; Akutsu H; Noguchi M; Kato Y; Yamamoto T; Matsumura A
Brain Tumor Pathol; 2016 Apr; 33(2):107-16. PubMed ID: 26968173
[TBL] [Abstract][Full Text] [Related]
7. Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma.
Chen L; Voronovich Z; Clark K; Hands I; Mannas J; Walsh M; Nikiforova MN; Durbin EB; Weiss H; Horbinski C
Neuro Oncol; 2014 Nov; 16(11):1478-83. PubMed ID: 24860178
[TBL] [Abstract][Full Text] [Related]
8. TERT Promoter Mutation Analysis to Distinguish Glioma From Gliosis.
Hewer E; Phour J; Gutt-Will M; Schucht P; Dettmer MS; Vassella E
J Neuropathol Exp Neurol; 2020 Apr; 79(4):430-436. PubMed ID: 32068851
[TBL] [Abstract][Full Text] [Related]
9. Noninvasively evaluating the grading and IDH1 mutation status of diffuse gliomas by three-dimensional pseudo-continuous arterial spin labeling and diffusion-weighted imaging.
Liu T; Cheng G; Kang X; Xi Y; Zhu Y; Wang K; Sun C; Ye J; Li P; Yin H
Neuroradiology; 2018 Jul; 60(7):693-702. PubMed ID: 29777252
[TBL] [Abstract][Full Text] [Related]
10. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing.
Agarwal S; Sharma MC; Jha P; Pathak P; Suri V; Sarkar C; Chosdol K; Suri A; Kale SS; Mahapatra AK; Jha P
Neuro Oncol; 2013 Jun; 15(6):718-26. PubMed ID: 23486690
[TBL] [Abstract][Full Text] [Related]
11. Brain T1ρ mapping for grading and IDH1 gene mutation detection of gliomas: a preliminary study.
Cao M; Ding W; Han X; Suo S; Sun Y; Wang Y; Qu J; Zhang X; Zhou Y
J Neurooncol; 2019 Jan; 141(1):245-252. PubMed ID: 30414094
[TBL] [Abstract][Full Text] [Related]
12. Value and limitations of immunohistochemistry and gene sequencing for detection of the IDH1-R132H mutation in diffuse glioma biopsy specimens.
Preusser M; Wöhrer A; Stary S; Höftberger R; Streubel B; Hainfellner JA
J Neuropathol Exp Neurol; 2011 Aug; 70(8):715-23. PubMed ID: 21760534
[TBL] [Abstract][Full Text] [Related]
13. A novel high-sensitivity assay to detect a small fraction of mutant IDH1 using droplet digital PCR.
Hirano M; Ohka F; Maeda S; Chalise L; Yamamichi A; Aoki K; Kato A; Tanahashi K; Motomura K; Nishimura Y; Hara M; Shinjo K; Kondo Y; Wakabayashi T; Natsume A
Brain Tumor Pathol; 2018 Apr; 35(2):97-105. PubMed ID: 29460200
[TBL] [Abstract][Full Text] [Related]
14. New insights into glioma classification based on isocitrate dehydrogenase 1 and 2 gene status.
Shibahara I; Sonoda Y; Kanamori M; Saito R; Kumabe T; Tominaga T
Brain Tumor Pathol; 2011 Jul; 28(3):203-8. PubMed ID: 21735252
[TBL] [Abstract][Full Text] [Related]
15. Characterizing invading glioma cells based on IDH1-R132H and Ki-67 immunofluorescence.
Sabit H; Nakada M; Furuta T; Watanabe T; Hayashi Y; Sato H; Kato Y; Hamada J
Brain Tumor Pathol; 2014 Oct; 31(4):242-6. PubMed ID: 24384677
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral Susceptibility Signals Reflect Biomarker Status in Gliomas.
Kong LW; Chen J; Zhao H; Yao K; Fang SY; Wang Z; Wang YY; Li SW
Sci Rep; 2019 Nov; 9(1):17080. PubMed ID: 31745161
[TBL] [Abstract][Full Text] [Related]
17. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors.
Capper D; Weissert S; Balss J; Habel A; Meyer J; Jäger D; Ackermann U; Tessmer C; Korshunov A; Zentgraf H; Hartmann C; von Deimling A
Brain Pathol; 2010 Jan; 20(1):245-54. PubMed ID: 19903171
[TBL] [Abstract][Full Text] [Related]
18. Comparative study of IDH1 mutations in gliomas by high resolution melting analysis, immunohistochemistry and direct DNA sequencing.
Li J; Zhang H; Wang L; Yang C; Lai H; Zhang W; Chen X; Wang J
Mol Med Rep; 2015 Sep; 12(3):4376-4381. PubMed ID: 26130305
[TBL] [Abstract][Full Text] [Related]
19. Subgroup characteristics of insular low-grade glioma based on clinical and molecular analysis of 42 cases.
Tang C; Zhang ZY; Chen LC; Sun Z; Zhang Y; Qin Z; Yao Y; Zhou LF
J Neurooncol; 2016 Feb; 126(3):499-507. PubMed ID: 26586262
[TBL] [Abstract][Full Text] [Related]
20. Rapid and sensitive intraoperative detection of mutations in the isocitrate dehydrogenase 1 and 2 genes during surgery for glioma.
Kanamori M; Kikuchi A; Watanabe M; Shibahara I; Saito R; Yamashita Y; Sonoda Y; Kumabe T; Kure S; Tominaga T
J Neurosurg; 2014 Jun; 120(6):1288-97. PubMed ID: 24745708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]